Natera, Inc.

Investigation
04/19/2022

Initial Lawsuit
04/27/2022

Lawsuit Progression
06/27/2022

Investigation

Continous Holding
February 26, 2020 to April 19, 2022
Proposed Claim
Securities Violation

Investors investigation into Natera’s statements about Panorama’s reliability, accuracy, superiority to competing tests, and company growth driven by its technology and customer experience.

Main Event

New York Times Reports "Tests are Usually Wrong"

01/01/2022

News Outlets

The New York Times publishes an investigative report on non-invasive prenatal test (NIPTs) manufactured by Natera and other diagnostic testing companies. “The tests initially looked for Down syndrome and worked very well. But as manufacturers tried to outsell each other, they began offering additional screenings for increasingly rare conditions. The grave predictions made by those newer tests are usually wrong, an examination by The New York Times has found.”

“In a recent study, Natera said that its latest algorithm would identify about an equal number of false positives. But that same study included the results from when the tests were actually taken. Those numbers suggest there would be three times as many false positives as actual cases.“

The stock impact compares the closing price immediately preceding the date of the event and the following closing price. The price difference also reflects the overall mix of information.

Stock Impact

Close	Previous close	Price variation	Percentage variation
$91.33	$93.39	$-2.06	-2.21%

See more on Factual Timeline

Initial Lawsuit

First Complaint - 04/27/2022

This is a class action lawsuit on behalf of a class of all persons and entities who purchased or otherwise acquired Natera common stock between February 26, 2020, and April 19, 2022, inclusive.

Filing Date
04/27/2022
Class Period
02/26/2020 to 04/19/2022
Transgression
Securities Violation
Filing Firms
Kessler Topaz Meltzer & Check, LLP
Nix Patterson, LLP
Case Title
Schneider v. Natera, Inc. et al
Docket Number
1:22-cv-00398
Court
Texas Western District Court
Free File
Complaint

Allegations

According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:

(1) Panorama was not reliable and resulted in high rates of false positives;
(2) Prospera did not have superior precision compared to competing tests;
(3) as a result of defendants’ false and misleading claims about Natera’s technology, the company was exposed to substantial legal and regulatory risks;
(4) Natera relied upon deceptive sales and billing practices to drive its revenue growth; and
(5) as a result of the foregoing, defendants’ statements about the company’s business, operations, and prospects lacked a reasonable basis.